Browsing by publication type "Thesis or Dissertation"
Now showing items 21-40 of 169
-
Circulating tumour DNA analysis in advanced breast cancer
(Institute of Cancer Research (University Of London), 2022-10-17)Circulating tumour DNA (ctDNA) analysis shows great potential both as an approach to understand the evolution of advanced breast cancer (ABC) and as a clinical tool to assist in ABC management. ctDNA analysis has not yet ... -
Circulating tumour DNA in advanced thyroid cancer
(Institute of Cancer Research (University Of London), 2021-02-28)Conventional biomarkers currently used in thyroid cancer are not disease specific and fluctuate in advanced disease, making interpretation difficult. Circulating tumour DNA (ctDNA) has been shown to be a useful in other ... -
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ... -
Combining large scale in silico analysis with fragment screening to identify novel, ligandable secondary sites in cancer-associated proteins
(Institute of Cancer Research (University Of London), 2020-01-31)Proteins often have multiple binding sites involved in interactions with other molecules. The majority of currently approved drugs bind a protein's primary site, the major functional site in the protein. Targeting the ... -
The comprehensive proteomic characterisation of soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-01-04)Soft tissue sarcomas (STS) are a group of rare and heterogeneous mesenchymal malignancies. The extensive clinical and biological heterogeneity of STS complicates clinical disease management, and in the advanced setting ... -
Computational science-enabled radiological pathology for the non-invasive mapping of tumour heterogeneity in childhood neuroblastoma
(Institute of Cancer Research (University Of London), 2021-01-31)Neuroblastoma is a common childhood solid tumour that accounts for 15% of all cancer paediatric deaths. This thesis addresses key deficiencies in our ability to define, monitor and predict neuroblastoma heterogeneity for ... -
ctDNA guided diagnosis and management of gastrointestinal cancers
(Institute of Cancer Research (University Of London), 2023-07-05)Gastrointestinal (GI) cancers including pancreatic (PC), biliary tract (BTC) and colorectal cancers (CRC) rely on a tissue biopsy through invasive procedures such as endoscopies and colonoscopies. Timely diagnosis of these ... -
Deciphering evolutionary trajectories in hereditary renal cell carcinomas
(Institute of Cancer Research (University Of London), 2024-01-16)Establishing the limits of predictability in cancer evolution has significant implications for precision medicine. Clear cell renal cell carcinoma (ccRCC) follows highly deterministic evolutionary pattern with conserved ... -
Deciphering genetic susceptibility to multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)Multiple myeloma (MM) is a malignancy characterised by the clonal expansion of plasma cells primarily from the bone marrow. The two- to four-fold increased risk observed in relatives of MM patients provides support for ... -
Deciphering the genomic landscape and evolution in multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)Multiple myeloma (MM) is the second commonest haematological cancer in Western countries, with most patients dying from progressive disease after relapse. Currently, the molecular mechanisms responsible for the initiation ... -
Deconstructing the soft tissue sarcoma matrisome and adhesome for drug target and biomarker discovery
(Institute of Cancer Research (University Of London), 2023-12-08)Soft tissue sarcomas (STS) are a rare and diverse group of mesenchymal malignancies that present significant challenges in clinical management due to their extensive clinical and biological heterogeneity. STS have a dismal ... -
Defining novel immune biomarkers of prognosis and immunotherapy sensitivity in gastro-oesophageal and colorectal cancers
(Institute of Cancer Research (University Of London), 2023-11-28)Background Gastro-oesophageal adenocarcinomas (GOAs) frequently recur after resection; prognostic and predictive markers are absent. Mismatch repair-deficient (MMRd) GOAs have high mutational burden, are frequently ... -
Defining the mechanisms of multi-target tyrosine kinase inhibitor resistance in soft tissue sarcoma
Soft tissue sarcomas (STS) are a rare, heterogeneous, and challenging group of cancers to treat effectively. The approval of pazopanib, as well as promising clinical trial data for a number of other multi-target tyrosine ... -
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ... -
Design and synthesis of bifunctional molecules for directing phosphorylation
(Institute of Cancer Research (University Of London), 2023-05-04)The field of bifunctional molecules such as PROTAC, DUBTAC and PhoRC has demonstrated that inducing proximity between two protein complexes is sufficient to redirect post-translational modifications (PTMs), and effect ... -
Design and synthesis of dual kinase-bromodomain inhibitors targeting ALK and BRD4
(Institute of Cancer Research (University Of London), 2019-12-31)Neuroblastoma is a paediatric cancer of neural crest origin and is the most common extracranial tumour in childhood. In high-risk patients with poor clinical outcome, mutations within the kinase domain of anaplastic lymphoma ... -
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30) -
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ... -
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27) -
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ...